Catalyst
Slingshot members are tracking this event:
Merck's (MRK) Keytruda Approved By FDA for New Indication in Metastatic Non-Small Cell Lung Cancer (NSCLC) With High PD-L1 Expression and No EGFR or ALK Mutations
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 24, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Keytruda, Fda, Metastatic Non-small Cell Lung Cancer, Nsclc, High Pd-l1 Expression, No Egfr, Alk, Mutations
